Drug Trial Radar · NCT05560646
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
Last checked: Nov 19, 2026Latest source record: May 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
354
Actual
Start
Oct 25, 2022
Primary completion
May 28, 2025
Study completion May 28, 2025
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- Collaborators
- IQVIA Pty Ltd
- First posted
- Sep 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 49 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain.
Conditions
- Endometriosis
Interventions
OG-6219Drug
OG-6219 Dose 1, Dose 2, Dose 3 BID: Participants will receive (orally) OG-6219 tablets during treatment cycles.
PlaceboDrug
Participants will receive (orally) OG-6219 Placebo tablets BID during treatment cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline Cycle in Mean Overall Pelvic Pain Score at Treatment Cycle 3Time frame: Baseline Cycle (up to Day -28) and Treatment Cycle 3 (Day 95). Each cycle was referred to 1 menstrual cycle (approximately 21 to 32 days).
- Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)Time frame: From the first dose administration of the study drug (Day 1) up to 14 days after the last dose of study drug administration, approximately 108 days
- Percentage of Participants With Treatment-Emergent Adverse Events Leading to Study Treatment DiscontinuationTime frame: From the first dose administration of the study drug (Day 1) up to 14 days after the last dose of study drug administration, approximately 108 days
Locations
86 sites in 11 countries. Site status is shown where the registry gives one.
Central Research Associates LLC dba Flourish Research
Birmingham, Alabama
UAB Center for Women's Reproductive Health
Birmingham, Alabama
Olympia Clinical Trials
Los Angeles, California
Yale Fertility Center
Orange, Connecticut
Physician Care Clinical Research, LLC
Sarasota, Florida
University of South Florida
Tampa, Florida
MediSense Inc
Atlanta, Georgia
Paramount Research Solutions
College Park, Georgia
Infinite Clinical Trials
Morrow, Georgia
The Advanced Gynecologic Surgery Institute
Park Ridge, Illinois
Ochsner Health Center - Baptist McFarland Medical Plaza
New Orleans, Louisiana
Omni Fertility and Laser Institute
Shreveport, Louisiana
John Hopkins University
Baltimore, Maryland
Bosque Women's Care
Albuquerque, New Mexico
University of Cincinnati
Cincinnati, Ohio
Centricity Research Dublin
Dublin, Ohio
Penn State Health Women's Health Clinic
Hershey, Pennsylvania
Clinical Research of Philadelphia, LLC
Philadelphia, Pennsylvania
Palmetto Clinical Research
Summerville, South Carolina
Chattanooga Medical Research, LLC
Chattanooga, Tennessee
Cedar Health Research, LLC
Euless, Texas
The Women's Hospital of Texas
Houston, Texas
Clinical Trial Network LLC
Houston, Texas
Northeast Clinical Research of San Antonio
San Antonio, Texas
Wasatch Clinical Research
Salt Lake City, Utah
Tidewater Clinical Research
Norfolk, Virginia
Seattle Women's: Health, Research, Gynecology
Seattle, Washington
Cliniques Universitaires Saint-Luc
Brussels, Belgium
AZ Jan Palfijn Gent
Ghent, Belgium
Universitair Ziekenhuis Ghent
Ghent, Belgium
Jessa Ziekenhuis Hospital
Hasselt, Belgium
CHU de Tivoli
La Louvière, Belgium
Medical Center Repromed EOOD
Pleven, Bulgaria
UMHAT "Sv. Georgi", EAD
Plovdiv, Bulgaria
DCC " Ascendent" EAD
Sofia, Bulgaria
SHATOD - Sofia District, EOOD
Sofia, Bulgaria
MHAT for women's health - Nadezhda, OOD
Sofia, Bulgaria
DCC "Alexandrovska", EOOD
Sofia, Bulgaria
Medical Center Hera EOOD
Sofia, Bulgaria
Group practice for specialized medical care in the field of obstetrics and gynecology - Gin Art OOD
Sofia, Bulgaria
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.